CAS 1610353-18-8: Immunoglobulin G2, anti-(human interleukin 23) (human monoclonal MEDI2070 heavy chain), disulfide with human monoclonal MEDI2070 λ-chain, dimer

Description: Immunoglobulin G2 (IgG2), specifically the anti-human interleukin 23 (IL-23) monoclonal antibody MEDI2070, is a therapeutic protein designed to target and neutralize IL-23, a cytokine involved in inflammatory processes and autoimmune diseases. This dimeric structure consists of two heavy chains and two light chains, linked by disulfide bonds, which contribute to its stability and functionality. IgG2 is characterized by its ability to bind specifically to IL-23, inhibiting its interaction with receptors on immune cells, thereby modulating immune responses. The heavy chain of MEDI2070 is derived from human sources, ensuring reduced immunogenicity when administered to patients. This monoclonal antibody exhibits high specificity and affinity for its target, making it a valuable tool in the treatment of conditions such as psoriasis and inflammatory bowel disease. The CAS number 1610353-18-8 uniquely identifies this compound, facilitating its recognition in scientific literature and regulatory contexts. Overall, MEDI2070 represents a significant advancement in targeted biologic therapies aimed at controlling inflammatory pathways.

Formula: Unspecified

Synonyms:

• MEDI 2070
• AMG 139
• Immunoglobulin G2, anti-(human interleukin 23) (human monoclonal MEDI2070 heavy chain), disulfide with human monoclonal MEDI2070 λ-chain, dimer
• Immunoglobulin G2-lambda, anti-(human interleukin-23 (IL-23)); human monoclonal antibody:γ2 heavy chain (1-450) [human VH (Homo sapiens IGHV3-33*01 (99%) ?(IGHD)-IGHJ3*02) [8.8.17] (1-124) -Homo sapiens IGHG2*01 (125-450)] (138-216′)-disulfide with lambda light chain (1′-217′) [human V-LAMBDA (Homo sapiens IGLV1-40*01 (96%) -IGLJ3*02 (92%)) [9.3.11] (1′-111′) -Homo sapiens IGLC2*01 (112′-217′)], dimer (226-226′′:227227′′:230-230′′:233-233′′)-tetrakisdisulfide
• Brazikumab

Brazikumab

CAS: 1610353-18-8

Brazikumab (AMG 139) is a humanized antibody targeting IL-23 by binding to the P19 subunit, …

• Purity: 95% - 95%
• Color and Shape: Liquid

Brazikumab

CAS: 1610353-18-8

Anti-IL23 human monoclonal antibody; used as a treatment of Crohn's disease